Alnylam Pharmaceuticals, Inc.
ALNYLast close · Oct 16, 2026231.83−2.20 (−0.94%)
Market cap$31.0B
13 firms' latest targets, last 90 days: median $345.00 ($253.00–$455.00), 49% above the last close.
Price and published targets
Each firm's latest target
| Date | Firm | Target | Change | Vs price now |
|---|---|---|---|---|
| 2026-10-15 | UBS | $354.00 | ▼ 36% | +53% |
| 2026-10-14 | Wells Fargo | $253.00 | ▼ 1% | +9% |
| 2026-10-08 | RBC Capital | $345.00 | ▼ 1% | +49% |
| 2026-09-08 | Jefferies | $260.00 | ▲ 13% | +12% |
| 2026-08-25 | Bernstein | $376.00 | ▼ 16% | +62% |
| 2026-08-18 | BMO Capital | $318.00 | — | +37% |
| 2026-08-04 | H.C. Wainwright | $455.00 | ▼ 6% | +96% |
| 2026-08-04 | Truist | $315.00 | ▼ 23% | +36% |
| 2026-08-03 | Barclays | $450.00 | ▼ 15% | +94% |
| 2026-07-31 | Raymond James | $420.00 | ▼ 10% | +81% |
| 2026-07-31 | Oppenheimer | $350.00 | ▼ 30% | +51% |
| 2026-07-31 | Morgan Stanley | $300.00 | ▼ 25% | +29% |
| 2026-07-31 | Stifel | $318.00 | ▼ 28% | +37% |
Consensus estimates
| FY | Revenue | YoY | EPS | YoY | Revenue range | EPS range | Analysts |
|---|---|---|---|---|---|---|---|
| 2023reported | $1.8B | +76% | -$3.52 | — | est. $1.8B+0% | est. -$3.48 | 17 |
| 2024reported | $2.2B | +23% | -$2.18 | — | est. $2.2B+0% | est. -$2.06 | 20 |
| 2025reported | $3.7B | +65% | $2.33 | — | est. $3.8B-1% | est. $2.46 | 18 |
| 2026 | $5.5B | +47% | $6.66 | +171% | $5.4B–$5.7B | $6.22–$7.18 | 20 |
| 2027 | $6.9B | +27% | $10.02 | +50% | $6.2B–$7.9B | $7.25–$11.44 | 20 |
| 2028 | $8.3B | +19% | $12.34 | +23% | $6.6B–$9.9B | -$2.18–$18.63 | 22 |
| 2029 | $9.3B | +13% | $14.38 | +17% | $8.4B–$10.5B | $12.58–$16.62 | 14 |
| 2030 | $10.6B | +13% | $16.10 | +12% | $9.5B–$11.8B | $14.09–$18.62 | 11 |
Targets, grades and estimates are quoted from third parties (via Financial Modeling Prep) and are theirs, not ours; each target links to the report it was published in. A firm counts once, at its latest target or grade.